Patients in England diagnosed with a specific form of incurable breast cancer can now receive a life-prolonging medication through the National Health Service. This development arrives two years after health authorities initially rejected the treatment on financial grounds.
The pharmaceutical treatment, known as Enhertu, can extend a patient's life by an average of nearly seven months, with some individuals experiencing an extension of up to three years. Approximately 1,000 women annually with HER2-low breast cancer are expected to benefit from the updated prescribing guidelines.
Scotland has provided NHS access to the therapy since 2023, and it is currently utilized across 26 other European nations. Advocacy groups and affected individuals have maintained steady pressure for wider availability since the National Institute for Health and Care Excellence deemed the treatment financially unjustified in 2024.
Beginning Thursday, medical professionals throughout England gained authorization to prescribe the therapy, and Wales is anticipated to implement similar policies shortly. However, the updated recommendations do not automatically extend to Northern Ireland.
Health Secretary Yvette Cooper stated that the medication can profoundly alter lives and acknowledged the persistent efforts of campaigners who demanded wider access. Breast Cancer Now, a leading charity, noted that while the advocacy efforts ultimately succeeded, thousands of individuals missed out during the delay, and many have died.
Among those affected is Kate Wills, a 51-year-old mother with metastatic HER2-low breast cancer that has spread to her lungs and bones. Juggling a demanding career and family life, she described the waiting period as agonizing given that an effective treatment was known to exist. Upon learning of the NHS approval, she expressed immense relief and explained that the decision restored vital hope for her future.
Her children are in their teens and early twenties, and the treatment provides a realistic possibility of witnessing major life milestones. Yet, the milestone carries mixed emotions because several advocates and friends did not live long enough to receive the therapy. Among them was Jeannie Ambrose, who campaigned for the drug before passing away in January.
The medication developers, Daiichi Sankyo and AstraZeneca, did not significantly reduce their prices following the initial rejection. Instead, the reversal by health regulators followed a pharmaceutical pricing agreement tied to broader international trade discussions, which adjusted the financial thresholds health authorities apply when evaluating treatment costs relative to extended quality of life.
Reporting based on coverage first published by BBC News. Read the original report at BBC News.
